338 related articles for article (PubMed ID: 31919743)
41. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
Drugs; 2024 Jun; ():. PubMed ID: 38849701
[TBL] [Abstract][Full Text] [Related]
42. Eosinophilic Esophagitis: the Potential Role of Biologics in its Treatment.
Choudhury S; Baker S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):150-159. PubMed ID: 31175521
[TBL] [Abstract][Full Text] [Related]
43. Novel targeted therapies for eosinophilic disorders.
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J; Prussin C; Renzi P; Rothenberg ME; Roufosse F; Simon D; Simon HU; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2012 Sep; 130(3):563-71. PubMed ID: 22935585
[TBL] [Abstract][Full Text] [Related]
44. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
45. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.
Walsh GM
Curr Opin Mol Ther; 2009 Jun; 11(3):329-36. PubMed ID: 19479666
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Agarwal A; Spath D; Sherris DA; Kita H; Ponikau JU
Clin Rev Allergy Immunol; 2020 Oct; 59(2):141-149. PubMed ID: 31073812
[TBL] [Abstract][Full Text] [Related]
47. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
48. Anti-IL-5 in pediatric allergic diseases.
Tenero L; Arturi E; Piazza M; Piacentini G
Pediatr Allergy Immunol; 2020 Nov; 31 Suppl 26():14-16. PubMed ID: 33236428
[TBL] [Abstract][Full Text] [Related]
49. Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome.
Tajima K; Katagiri T
Dig Dis Sci; 1996 Feb; 41(2):282-8. PubMed ID: 8601370
[TBL] [Abstract][Full Text] [Related]
50. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
51. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.
Lombardi C; Berti A; Cottini M
Curr Res Immunol; 2022; 3():42-53. PubMed ID: 35496822
[TBL] [Abstract][Full Text] [Related]
52. Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome.
Sergew A; Fernández Pérez ER
Semin Respir Crit Care Med; 2016 Jun; 37(3):441-56. PubMed ID: 27231866
[TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
54. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
55. Causes of hypereosinophilia in 100 consecutive patients.
Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
[TBL] [Abstract][Full Text] [Related]
56. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
57. [Idiopathic eosinophilia].
Trüeb RM
Hautarzt; 1997 Mar; 48(3):153-6. PubMed ID: 9182084
[TBL] [Abstract][Full Text] [Related]
58. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
59. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
60. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
